No matches
Dermatology

Expert Insights on the Management of Bullous Pemphigoid: The Canadian Treatment Guidelines

Fiona Lovegrove, MD, PhD, reviews Canadian consensus recommendations for the diagnosis and management of bullous pemphigoid (BP).
Fiona Lovegrove
MD, PhD, FRCPC
Fiona Lovegrove

Related resources

The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

Infographic
Etiology and Diagnosis of Bullous Pemphigoid

Etiology and Diagnosis of Bullous Pemphigoid

expert video
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

expert video
Chronic Spontaneous Urticaria Mechanism of Disease Animation

Chronic Spontaneous Urticaria Mechanism of Disease Animation

videoanimation
Heterogeneous Clinical Presentations and Diagnostic Challenges With Bullous Pemphigoid (BP)

Heterogeneous Clinical Presentations and Diagnostic Challenges With Bullous Pemphigoid (BP)

expert video
Unmet Needs and Management Challenges in Bullous Pemphigoid (BP)

Unmet Needs and Management Challenges in Bullous Pemphigoid (BP)

expert video
Under the Skin: Autoimmunity and Type 2 Inflammation in Bullous Pemphigoid (BP)

Under the Skin: Autoimmunity and Type 2 Inflammation in Bullous Pemphigoid (BP)

expert video
Inside the Hive: ​Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

Inside the Hive: ​Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

expert video
Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid

Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid

expert video
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

expert video
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

expert video
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

expert video
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

expert video
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

expert video
KOL Video Interview – Dr. Eric Simpson

KOL Video Interview – Dr. Eric Simpson

expert video
Identifying BP: How do symptoms of BP and their severity alter patient diagnosis?

Identifying BP: How do symptoms of BP and their severity alter patient diagnosis?

expert video
Considerations for Disease Modification in AD

Considerations for Disease Modification in AD

expert video
IL-4 Contributes to Systemic Type 2 Inflammation in AD

IL-4 Contributes to Systemic Type 2 Inflammation in AD

expert video
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

slide presentation
KOL Video Interview – Dr Amy Paller

KOL Video Interview – Dr Amy Paller

expert video
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
KOL Video Interview – Dr Paula Luna

KOL Video Interview – Dr Paula Luna

expert video
Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

expert video
Clinical Assessment of Prurigo Nodularis

Clinical Assessment of Prurigo Nodularis

expert video
The Growing Burden: Cumulative Disease Impact and Comorbidities in Pediatric AD

The Growing Burden: Cumulative Disease Impact and Comorbidities in Pediatric AD

expert video
Beyond the Skin: Cumulative Disease Burden in Children With Atopic Dermatitis

Beyond the Skin: Cumulative Disease Burden in Children With Atopic Dermatitis

expert video
Barrier Breakdown: The Role of Type 2 Inflammation in AD and Atopic Sensitization

Barrier Breakdown: The Role of Type 2 Inflammation in AD and Atopic Sensitization

expert video
The Role of IL-4 and IL-13 in CSU

The Role of IL-4 and IL-13 in CSU

Infographic
Atopic Dermatitis and Prurigo Nodularis: Clarifying Perspectives and Common Misconceptions

Atopic Dermatitis and Prurigo Nodularis: Clarifying Perspectives and Common Misconceptions

expert video
Atopic Dermatitis: Pathomechanisms: Clarifying Perspectives and Misconceptions

Atopic Dermatitis: Pathomechanisms: Clarifying Perspectives and Misconceptions

expert video
CLCI in Atopic Dermatitis Infographic

CLCI in Atopic Dermatitis Infographic

Infographic
Exploring IL-31–mediated immune modulation and the role of IL-4 signaling in AD-related conjunctivitis

Exploring IL-31–mediated immune modulation and the role of IL-4 signaling in AD-related conjunctivitis

expert video
Evaluating the cytokine hierarchy in AD and the contributions of IL-4, IL-13, and IL-31 to itch

Evaluating the cytokine hierarchy in AD and the contributions of IL-4, IL-13, and IL-31 to itch

expert video
Differential Roles of IL-4 and IL-13 in AD Pathogenesis and B Cell Activation

Differential Roles of IL-4 and IL-13 in AD Pathogenesis and B Cell Activation

expert video
The Burden of Chronic Spontaneous Urticaria: One Patient’s Journey to Diagnosis

The Burden of Chronic Spontaneous Urticaria: One Patient’s Journey to Diagnosis

videoanimation
Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

videoanimation
The Burden of AD: More Than Skin Deep

The Burden of AD: More Than Skin Deep

Infographic
Type 2 Inflammation

Type 2 Inflammation

expert video
Potential for Disease Modification in Atopic Dermatitis

Potential for Disease Modification in Atopic Dermatitis

expert video
Atopic Dermatitis as a Risk Factor for the Development of Food Allergies

Atopic Dermatitis as a Risk Factor for the Development of Food Allergies

expert video
Shifting Gears: Can Disease Course Be Changed in Patients With Pediatric Atopic dermatitis?

Shifting Gears: Can Disease Course Be Changed in Patients With Pediatric Atopic dermatitis?

expert video
The Puzzle of Itch in Elderly Adults: Putting the Pieces Together

The Puzzle of Itch in Elderly Adults: Putting the Pieces Together

expert video
Unmasking Itch in Older Adults: Zooming in on the Unique Challenges

Unmasking Itch in Older Adults: Zooming in on the Unique Challenges

expert video
The Science Behind the Scratch: Pathophysiology of Age-Related Itch

The Science Behind the Scratch: Pathophysiology of Age-Related Itch

expert video
The Role of Type 2 Inflammation Across a Range of Pruritic Skin Diseases in Older Adults

The Role of Type 2 Inflammation Across a Range of Pruritic Skin Diseases in Older Adults

expert video
Importance of Early Diagnosis in Bullous Pemphigoid

Importance of Early Diagnosis in Bullous Pemphigoid

expert video
Risk of Mortality and Infections in Bullous Pemphigoid

Risk of Mortality and Infections in Bullous Pemphigoid

expert video
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

videoanimation

Learning objectives

  • Understand how clinical presentation and diagnostic testing are used to establish a diagnosis of BP
  • Recognize how disease severity, patient characteristics, and patient and caregiver preferences inform BP treatment selection
Tags
guidelinesdiagnosisClinical Managementcorticosteroidsbiologics
MAT-US-2611409 v1.0 - P 10/2026

About this expert

Dermatology

Fiona Lovegrove

MD, PhD, FRCPC

Founder & Dermatologist, Lovegrove Dermatology

See author’s profile
Fiona Lovegrove

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v4.0 – P Expiration Date: 10/16/2027

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region